Enhanced Early Detection of Breast Carcinoma by Fork head Box Protein - Lotfy, Effat Tharwat;El-Houseini, Motawa
36,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Breast cancer was the most common type of cancer among females worldwide and was the fourth most common cause of cancer-related deaths. Therefore this study designed to evaluate the gene expressions and protein levels of Foxp3, TGF-beta and VEGF genes in benign breast lesions and breast carcinoma as useful markers to enhance the early detection of breast cancer by different techniques and conducted on three groups; invasive breast carcinoma group, high risk patients with benign breast lesions and control group. In current study breast cancer patients recorded a highly significant increase in…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Breast cancer was the most common type of cancer among females worldwide and was the fourth most common cause of cancer-related deaths. Therefore this study designed to evaluate the gene expressions and protein levels of Foxp3, TGF-beta and VEGF genes in benign breast lesions and breast carcinoma as useful markers to enhance the early detection of breast cancer by different techniques and conducted on three groups; invasive breast carcinoma group, high risk patients with benign breast lesions and control group. In current study breast cancer patients recorded a highly significant increase in the mean value of serum VEGF, TGF-beta and Foxp3 protein level and gene expressions when compared to the high risk and the control groups. Meanwhile, the high risk had intermediate mean value of VEGF, TGF-beta and Foxp3 protein levels and gene expressions between breast cancer and healthy control. These results confirmed with three different techniques (ELISA, qRT-PCR and Flow cytometer). Therefore the levels of VEGF, TGF-beta and Foxp3 could be used as, quantitative, accurate, and a sensitive biomarkers and robust assay for the early detection of breast cancer especially in high risk patients .
Autorenporträt
Dr. Effat Tharwat studierte an der naturwissenschaftlichen Fakultät der Universität Kairo und war als leitender Spezialist für wissenschaftliche Forschung und medizinische Analysen in der Abteilung für Krebsbiologie am Nationalen Krebsinstitut der Universität Kairo tätig. M.Sc. der Umweltwissenschaften Studien und Forschungen, Ain Shams Universität. Promotion in Genetik an der wissenschaftlichen Fakultät der Al-Azhar-Universität.